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Molecular design of inhibitors for RNA methylation regulating enzymes 
The RNA m6A methylation plays crucial role in various physiological processes and therefore 
the development of chemical agents controlling this process has large biological and medical 
importance. In the present work, the results of the computational design of the inhibitory ligands 
for the enzymes regulating the RNA adenosine N6-methylation are presented. The structure of 
the enzyme-ligand complexes was established using the molecular docking and molecular 
dynamics approaches. The activity of the best predicted RNA m6A methyltransferase inhibitors 
was confirmed using enzyme inhibition and cell proliferation assays. These compounds are the 
first known RNA m6A methylation inhibitors and therefore of substantial interest for further 
biomedical studies. 
 
Keywords: epitranscriptomics, N-6-methyl-adenosine, RNA methylation, N6-Adenosine-
Methyltransferase, ligand binding, computer-aided design. 
CERCS code: P410 Theoretical chemistry, quantum chemistry  
RNA metüleerimist reguleerivate ensüümide inhibiitorite molekulaardisain  
RNA m6A metüleerimisel on suur roll erinevates füsioloogilistes protsessides ning sellest 
tulenevalt on seda protsessi kontrollivate keemiliste agentide arendamine suure bioloogilise ja 
meditsiinilise tähtsusega. Käesolevas töös esitatakse RNA adenosiini N6-metüleerimist 
reguleerivate ensüümide inhibiitorite molekulaardisaini tulemused. Vastavate ensüüm-ligand 
komplekside struktuurid leiti molekulaarsildamise ja molekulaardünaamika meetodite abil. 
Parimate RNA m6A metüültransferaasi inhibiitorite aktiivsused leidsid eksperimentaalset 
kinnitust ensüümi inhibeerimise ja rakkude proliferatsiooni katsetes. Nimetatud ühendid on 
esimesed teadaolevad RNA m6A metüleerimise inhibiitorid ning pakuvad seetõttu suurt huvi 
edasistes biomeditsiinilistes uuringutes. 
 
Märksõnad: epitranskriptoomika, N-6-metüül-adenosiin, RNA metüleerimine, N6-adenosiin-
metüültransferaas, ligandi sidumine, arvutipõhine disain.  
CERCS kood: P410 Teoreetiline ja kvantkeemia  
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Abbreviations 
3H-SAM – tritiated S-adenosyl-L-methionine 
3-meT – 3-methylthymidine  
3-meU – 3-methyluracil 
5mC – 5-methylcytosine 
6mA – N6-methyladenine 
AlkBH5 – AlkB family member 5 
ATP – adenosine triphosphate 
CpG – 5'-Cytosine- phosphate-Guanine-3' 
DE – docking efficiency 
DMEM – Dulbecco's modified eagle medium 
DNA – deoxyribonucleic acid  
DNMT – DNA methyltransferases 
DTT – dithiothreitol 
ECM – extracellular matrix 
ELISA – enzyme-linked immunosorbent assay 
ESC – embryonic stem cell 
FBS – fetal bovine serum 
FTO – fat mass and obesity-associated protein 
HEK – human embryonic kidney cells 293 
iCM – inducing functional cardiomyocyte 
IOX1 – 5-carboxy-8-hydroxyquinoline 
iPSC – induced pluripotent stem cell 
J – pseudouracil 
KLF4 – Kruppel-like factor 4 
m6A – N6-methyladenosine   
Mettl14 – methyltransferase-like 14 
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Mettl3 – methyltransferase-like 3  
mRNA – messenger RNA 
MYC – v-myc avian myelocytomatosis viral oncogene homolog 
N-CDPCB – N-(5-Chloro-2,4-dihydroxyphenyl)-1-phenylcyclobutane-carboxamide  
OCT4 – octamer-binding transcription factor 4 
PBS – phosphate buffered saline 
PFA – paraformaldehyde solution 4% in PBS 
RMSD – root mean square deviation 
RNA – ribonucleic acid  
RNaseOUT – recombinant RNase Inhibitor 
SAM – S-adenosylmethionine 
SOX2 – SRY (sex determining region Y)-box 2 
ss-RNA – single-stranded RNA 
TBS – tris-buffered saline 
Tris – tris(hydroxymethyl)aminomethane 
WST 1 – tetrazolium salt 
WTAP – Wilm's tumour-1-associated protein 
YTHDC1 – YTH domain-containing protein 1 
YTHDC2 – YTH domain-containing protein 2 
YTHDF1 – YTH N6-methyladenosine RNA binding protein 1 
YTHDF2 – YTH N6-methyladenosine RNA binding protein 2 
YTHDF3 – YTH N6-methyladenosine RNA binding protein 3 
ZIKV – Zika virus 
 
6 
 
1. Introduction 
The regenerative medicine has today high expectations as related to the reversible epigenetic 
regulation of the gene expression in diverse tissues of the organism. Differently from the direct 
gene regulation initiated by the modification of DNA code, the epigenetic change in gene 
expression does not result from alteration in DNA sequence [1], thus allowing larger flexibility 
and control of this process. The classic epigenetic mechanisms include DNA methylation, 
histone modifications, but also chromatin remodeling and regulation mediated by non-coding 
RNAs. In past few years, the interest in the study of global modification patterns to both coding 
and noncoding RNA has significantly increased. This new area of research called 
epitranscriptomics is expected to give essential information for understanding human health 
and molecular disease pathology. The central mechanism of the epigenetic modification of 
RNA is the methylation of the nucleic acid bases. The most common RNA base modification 
is N6-methyladenosine (m6A).  
Recently, it has been shown that m6A modifications of RNA affect its splicing, intracellular 
distribution, translation, and cytoplasmic degradation, playing thus a crucial role in regulating 
cell differentiation, neuronal signaling, carcinogenesis and immune tolerance [2]. The m6A 
presence in RNA is regulated by specific enzymes, i.e. the RNA methyltransferases, RNA 
methylases and RNA reader proteins. The regulation of these enzymes by suitable inhibitors or 
activators will thus enable the fine tuning of epitranscriptomic processes in biological and 
medical applications. Targeted development of small-molecule modulators (inhibitors and/or 
activators) of such enzymes involved in epitranscriptomic modulation would lead to 
compounds that control over the RNA methylation process, with potential outcomes for 
traditional and regenerative medicine. [3,4] In this study, we present the results of the 
computational molecular design of small-molecule inhibitors of enzymes involved in the 
regulation of RNA m6A methylation. 
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2. Literature overview 
2.1 Stem cells and epigenetic gene regulation 
Stem cells that can transdifferentiate to other types of cells have been highlighted as potentially 
transforming the whole regenerative medicine by enabling the direct repair or substitution of 
body tissues and organs [5]. However, there are several major obstacles in the way for their 
widespread use in clinical practice. First, because of their scarcity, it is very difficult to locate 
and separate the adult stem cells from tissues. Therefore, the embryonic stem cells (ESCs) are 
mostly used in laboratory and clinical investigations. This makes the research and clinical 
applications expensive and rises ethical problems with using the human embryos. [6] 
Furthermore, the differentiation of the stem cells into tissue cells is not strictly controlled and 
can lead to cancer [7,8].  
A major breakthrough in the stem cells research was made by Yamanaka and coworkers [9] 
who demonstrated that cells with a gene expression profile and developmental potential similar 
to embryonic stem cells (ESCs) can be generated from mouse fibroblasts by using a cocktail of 
four transcription factors. These stem cells were called induced pluripotent stem cells (iPSCs), 
and the transcription factors were named “Yamanaka factors” (OCT4, SOX2, KLF4 and MYC). 
It was soon proven that using iPSCs technology, the skin fibroblasts and terminally 
differentiated cells of other adult tissues can be transformed into cells similar to ESCs. [10,11] 
Moreover, it appeared that it is also possible to transform the adult tissue cells into cells of other 
lineages by passing the phase of pluripotency. This possibility is schematically illustrated on 
the modified Waddington model of the cell reprogramming (Figure 1). The tissue specific 
defined culture can transform skin cells to become trophoblast, heart valve cells, photoreceptor 
cells, immune cells, melanocytes, and so forth. Extracellular matrix complexation with iPSCs 
enables generation of tissue organoids for organs of the body. Transdifferentiation has been 
reported for various cell types such as pancreatic beta cells, neurons, hepatocyte-like cells, and 
haematopoietic progenitor cells. The functional cardiomyocytes (iCMs) have been directly 
transformed from fibroblasts. [12] 
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Figure 1. Modified Waddington Model for Cellular Reprogramming (from Srivastava et al) 
[13]. 
Important factors in the gene expression that regulate the cell pluripotency, differentiation or 
transdifferentiation are simple chemical modifications of DNA and histones in chromatin. 
These are known as the “epigenetic code” (Figure 2). [14] The main epigenetic modification of 
DNA is featured by methylation of cytosine residues in 5'-Cytosine-phosphate-Guanine-3' 
(CpG) sequence. The N-terminal tails of histone proteins are subject to a wide range of different 
modifications, including acetylation, methylation, phosphorylation and ubiquitylation. All of 
these chemical changes seem to have a substantial influence on chromatin structure and gene 
function, which differs depending on the type and location of the modification. [15] The DNA 
and histone lysine methylation essentially initiates the cell differentiation and development 
[16]. 
Whereas the epigenetic chemical modifications of DNA and histones have been relatively well 
investigated, the study of similar chemical modifications of RNA is still in its infancy [15]. 
Nevertheless, RNA chemical modifications have recently been identified to have an increasing, 
unprecedented and species-wide conserved impact on several critical cellular functions, such 
as proliferation, survival and differentiation, mostly through regulation of RNA stability 
[17,18,19]. The most abundant modification in eukaryotic messenger RNA is N6-
methyladenosine (m6A). In addition to mRNA, this modification also appears in long non-
coding RNAs [18] and microRNAs [19], thus covering the whole epitranscriptome. The m6A 
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modifications in RNA are essential for the development and functions of several tissues 
including liver, kidney and brain. In the adult brain, m6A modifications have been shown to 
affect neuronal functions and maturation. Given the major role of RNA modifications as 
controllers of a wide array of biological processes, it is not surprising that they have been 
associated with various pathologies such as several developmental and immunological 
disorders, obesity, diabetes, cancer as well as with cardiovascular, neuronal and infectious 
diseases. [20] 
 
Figure 2. Epigenetic regulation in eukaryotes [14]. 
 
2.2 Methylated modifications of nucleic acids 
The nucleic acid modifications play important biological regulatory roles, especially in the 
regulation of the gene expression. The most essential DNA, messenger RNA and long non-
coding RNA modifications are the 5-methylcytidine with its oxidative derivatives and N6-
methyladenine. 
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Another important RNA modification is pseudouracil (J). [21] 
 
The DNA methylation is generally associated with the regulation of gene expression. The 
chromatin structure is influenced by the methylation, but the effect may be dual. Namely, the 
DNA methylation in the promoter region of the nucleic acid is directly leading to the repression 
of transcription. DNA methylation may also attract the specific proteins (“readers”) acting as 
repressors of the transcription. On the other hand, the DNA methylation in the gene body area 
has positive correlation with gene expression. [21] 
The RNA chemical modifications do not affect nucleoside sequence in most cases, but are much 
more diverse and functionally versatile. This is due to the more complex post-transcriptional 
processing of the mRNA that involves alternatively joining introns and removing exons. 
Notably, chemical modification of RNA requires significant amounts of energy. The RNA 
methylation in cell is carried out by using S-adenosylmethionine (SAM) as the methyl donor. 
The synthesis of a SAM molecule requires the energy equal to hydrolyzing 12 to 13 ATP 
molecules. [22] 
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2.3 RNA methylation/demethylation 
Today, more than 140 types of post-transcriptional chemical modifications of RNAs have been 
identified. The most abundant modification is m6A that accounts for about 50% of total 
methylated ribonucleotides and is present in 0.1%–0.4% of all adenosines in total cellular 
RNAs. [23] The N-methylation of the adenosine is a reversible process, catalyzed by specific 
enzymes (Figure 4). Those include the RNA methyltransferase enzyme complex 
Mettl3/Mettl14/WTAP consisting of three components: Mettl3 (methyltransferase-like 3), 
Mettl14 (methyltransferase-like 14), and WTAP (Wilm's tumour-1-associated protein), called 
also the “writer” enzyme; the RNA demethylases FTO (fat mass and obesity-associated protein) 
and AlkBH5 (AlkB family member 5), called “erasers”. The fate of the RNA in post-
transcriptomic processes is also directed by the “reader” enzymes that recognize specific m6A 
methylation in RNA. Several RNA reader enzymes have been identified, i.e. YTHDF1 (YTH 
N6-Methyladenosine RNA Binding Protein 1), YTHDF2 (YTH N6-Methyladenosine RNA 
Binding Protein 2) YTHDF3 (YTH N6-Methyladenosine RNA Binding Protein 3), YTHDC1 
(YTH domain-containing protein 1) and YTHDC2 (YTH domain-containing protein 2). [24] 
These three types of enzymes collectively coordinate the m6A RNA methylome in the 
eukaryotic cell.  
 
Figure 4. Dynamic and reversible m6A methylation in RNA (SAM – S-adenosyl-L-
methionine; SAH – S-adenosyl-L-homocystein) [25]. 
 
2.3.1 Writers 
The RNA methyltransferase enzyme complex Mettl3/Mettl14/WTAP is located in the nuclear 
speckle, and catalyzes the transfer of methyl groups from S-adenosyl-L-methionine (SAM) to 
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the specific adenines on the target RNAs. The reaction product is S-adenosyl-L-homocystein 
(SAH). [26] 
Notably, Mettl3 and Mettl14 were demonstrated to be the catalytic subunits, whereas WTAP 
controls the process [26]. The hypothetic chemical mechanism on the nucleic acid m6A 
methylation has been suggested in the case of DNA methyltransferase DNMT1 (Figure 5). 
 
Figure 5. Hypothetic mechanism of the m6A methylation of DNA by DNA methyltransferase 
DNMT1. [27] 
The catalytic centre of DNMT1 involves Asp65 and the peptide bond carbonyl oxygen between 
Pro66 and Pro67 residues [27]. From the principle of rationality in nature, it is feasible to 
assume a similar m6A methylation mechanism in the case of RNA (of course, with the 
applicable amino acid residues). 
The crystal structures of the Mettl3/Mettl14 protein complex together with SAM and SAH 
ligands, respectively, have been published recently by several groups [26,28,29,30] (Figure 6). 
From these structures, it was established that in Mettl3 the catalytic cavity might be fenced in 
by three major loops: the two loops near the perimeter of the SAM binding site, and a third, 
larger loop that makes extensive contact with Mettl14 [29].  
These crystal structures can be a basis for the rational target-based design of efficient small-
molecule ligands, acting as the inhibitors of the RNA methylation. 
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Figure 6. Crystal structure of the catalytic domain of Mettl3/Mettl14 complex with SAH by 
chain (pdb:5K7W) [29]. 
2.3.2 Erasers 
Two enzymes have been identified as responsible for the RNA m6A demethylation. The first 
of these is the fat mass and obesity-associated protein FTO. It was shown that FTO 
demethylates m6A containing RNA efficiently in vitro [31].  The crystal structure of the FTO 
in complex with 3-methylthymidine (3-meT) was first reported by Han and colleagues in 2010 
(pdb:3LFM) [32]. The structural analysis indicated that the hydrogen-bonding interaction 
between FTO and two carbonyl oxygen atoms in 3-meT or 3-methyluracil (3-meU) enables 
FTO to distinguish 3-meT or 3-meU from other nucleotides. Moreover, FTO contains an amino-
terminal AlkB-like domain and a carboxyl-terminal domain with a novel fold, which interact 
with each other and involve in FTO catalytic activity. The difference between FTO and other 
AlkB family members is that FTO has an extra loop covering one side of the conservative jelly-
roll motif, which can selectively compete with the unmethylated strand of the DNA duplex for 
binding to FTO. [31,32] 
Thereafter, a series of crystal structures FTO in complex with different inhibitory ligands have 
been published [33,34,35] that enable the target-based computational design of novel efficient 
inhibitors. An exemplary crystal structure of the complex between FTO and its inhibitor 
meclofenamic acid is given on Figure 7.  
 
14 
 
 
Figure 7. Crystal structure of FTO bound to a selective inhibitors meclofenamic acid, N-
oxalylglycine and glycerol by secondary structure (pdb:4QKN) [35]. 
Recently the crystal structures of another RNA demethylase AlkBH5 with various ligands were 
published [36]. The structure of AlkBH5 in complex with α-ketoglutarate is presented on Figure 
8. 
 
Figure 8. Crystal structure of human ALKBH5 in complex with -ketoglutarate by secondary 
structure (pdb:4NRO) [36]. 
2.3.3 Readers 
Decoding of the information engraved in the methyl code is executed by a special category of 
proteins called m6A readers, which can function in several ways. The presence of m6A in a 
target RNA alters the secondary or tertiary structure of its specific domain, which promotes 
binding of the m6A reader. This, in turn, locally remodels the RNA-protein interface to create 
another binding site for a second protein. Binding of the latter component (which might be 
involved in mRNA biogenesis, splicing, or decay) may thereby alter the fate of the target RNA. 
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Alternatively, the altered local secondary/tertiary structure in the target RNA induced by m6A 
may remodel the already bound protein(s) at that site to facilitate the binding of the m6A reader. 
Either of these outcomes can subsequently influence the processes that modulate the fate of a 
target mRNA, such as its export, translation, or stability. [2] 
The crystal structures of all three known RNA m6A readers (YTHDF1 [37], YTHDF2 [38], 
YTHDC1 [39]) together with various ligands and/or RNA have been published (Figure 9). 
 
Figure 9. Crystal structure of RNA m6A readers with ligands. Crystal structure of YTHDF1 
YTH domain in complex with 5mer m6A RNA (pdb:4RCJ) [37] (a); Crystal structure of 
YTH-YTHDF2 in complex with m6A (pdb:4RND) [38] (b); Crystal structure of YTHDC1 
YTH domain in complex with 5mer m6A RNA (pdb:4R3I) [39] (c). 
 
2.4 RNA methylation/demethylation inhibitors and activators 
Very little is presently known about the inhibitors or activators of the RNA methylation or 
demethylation enzymes.  
Using a structure-based virtual screening, Chen et al [40] found that rhein is an inhibitor of 
FTO.  
 
 
16 
 
Rhein can increase the cellular contents of m6A in mRNA by binding to the FTO active site 
and preventing FTO from binding to m6A substrate [40]. Rhein displays some selectivity on 
AlkB subfamily too. Meclofenamic acid is another highly selective inhibitor of FTO by 
competition for FTO binding with dm6A-containing substrate. However, MA does not bind to 
AlkBH5 in vitro and it cannot inhibit AlkBH5 demethylation activity, suggesting its target 
selection on FTO over AlkBH5 [41]. Moreover, citrate that adopts different binding patterns 
with FTO and AlkBH5 can act as an inhibitor for these human m6A demethylases [42]. 
Furthermore, IOX3 that covalently binds to Cys200 residue positioned outside of the active site 
of AlkBH5 also can be used as a small molecule inhibitor of AlkBH5 [43]. N-(5-Chloro-2,4-
dihydroxyphenyl)-1-phenylcyclobutane-carboxamide (N-CDPCB) is found to be another 
inhibitor of the FTO. The crystal structure of human FTO with N-CDPCB reveals a novel 
binding site for the FTO inhibitor and defines the molecular basis for recognition by FTO of 
the inhibitor. The identification of the new binding site offers new opportunities for further 
development of selective and potent inhibitors of FTO. [44] 
Up to date, no RNA methyltransferase or reader enzyme inhibitors have been reported. 
Therefore, the main objective of our present research has been to discover such inhibitors and/or 
enzyme activators. 
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3. Methodology 
3.1 Molecular docking 
Three most important enzymes involved in the RNA m6A methylation/demethylation were 
chosen for finding their efficient ligands using molecular modeling. Those were the RNA 
methyltransferase complex Mettl3/Mettl14, RNA demethylase FTO and RNA m6A reader 
YTHDF1. 
Several crystal structures of the Mettl3/Mettl14 complex are available at the Protein Data Bank 
[28], reported by different groups [26,28,29,30]. We selected the structure of the Mettl3/Mettl14 
complex with the S-adenosyl-L-homocysteine (SAH) as describing the potential target binding 
site for a small-molecule inhibitor. The crystal structure of this complex (pdb:5K7W) had been 
measured by X-ray diffraction with resolution 1.65 Å. It has been suggested that Mettl3 may 
be the only active methyltransferase in the heterodimeric complex. [29]  
The crystal structure of the RNA demethylase FTO has been published as for the pure protein 
[32] and together with different ligands [33,34,35]. Crystal structure of FTO in complex with 
5-carboxy-8-hydroxyquinoline (pdb:4IE4) was chosen for further molecular docking modeling. 
The structure had been determined using X-ray diffraction with the resolution 2.5 Å. [33] The 
choice of this RNA demethylase was made on the basis of the availability of the ligand 
compounds. 
In the case of RNA m6A readers, most experimental information is known for the YTHDF1 
enzyme. Therefore, the crystal structure of YTHDF1 together with pentamer m6A RNA was 
used for the molecular docking modeling (pdb:4RCJ). The X-ray diffraction structure of the 
protein had been measured with the resolution 1.6 Å. [37] 
The raw crystal structures were corrected and hydrogen atoms were automatically added to the 
protein using Schrödinger’s Protein Preparation Wizard of Maestro 10.7 [45]. 
AutoDock Vina 1.1.2 [46] was used for the docking studies to find out binding modes and 
binding energies of ligands to the receptor. The number of rotatable bonds of ligand was set by 
default by AutoDock Tools 1.5.6 [47]. However, if the number was greater than 6, then some 
of rotatable bonds were made as non-rotatable, otherwise calculations can be inaccurate. The 
active site, was surrounded with a grid-box sized 65 × 65 × 65 points with spacing of 1.0 Å. 
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The AutoDock 4.2 force field [47] was used in all molecular docking simulations. The docking 
efficiencies (DE) were calculated as follows 
𝐷𝐸 =
Δ𝐺𝑑𝑜𝑐𝑘
𝑁
                                                   (1) 
where  Δ𝐺𝑑𝑜𝑐𝑘 is the docking free energy and N – the number of non-hydrogen (“heavy”) atoms 
in the ligand molecule. 
The structure of ligand molecules was optimized using the density functional theory B3LYP 
method [48] with 6-31G basis set. 
The molecular dynamics simulations were carried out using Desmond simulation package of 
Schrödinger LLC. [49] The NPT ensemble with the temperature 300 K and pressure 1 bar was 
applied in all runs. The simulation lengths were 10 ns and 50 ns with relaxation time 1 ps.  The 
OPLS_2005 force field parameters were used in all simulations [50]. The long range 
electrostatic interactions were calculated using the Particle Mesh Ewald method [51]. The 
cutoff radius in Coloumb´ interactions was 9.0 Å. The water molecules were described using 
SPC (simple point charge) model. [52] The Martyna-Tuckerman-Klein chain coupling scheme 
[53] with a coupling constant of 2.0 ps was used for the pressure control and the Nosé-Hoover 
chain coupling scheme [53] for the temperature control. Non-bonded forces were calculated 
using an r-RESPA integrator where the short range forces were updated every step and the long 
range forces were updated every three steps. The trajectories were saved at 4.8 ps intervals for 
analysis. The behavior and interactions between the ligands and enzyme were analyzed using 
the Simulation Interaction Diagram tool implemented in Desmond molecular dynamics 
package. The stability of molecular dynamics simulations was monitored by looking on the root 
mean square deviation (RMSD) of the ligand and protein atom positions in time. For a system 
involving N atoms, RMSD is defined as follows: 
𝑅𝑀𝑆𝐷 = √
1
𝑁
∑ (𝑟𝑎𝑗 − 𝑟𝑎𝑖)
2𝑁
𝑎=1                                       (2) 
where 𝑟𝑎𝑖 and 𝑟𝑎𝑗 are the position vectors of atom a at the consecutive time moments i and j, 
respectively. 
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3.2. Experimental 
3.2.1. Cell culture  
HEK-293 (ATCC®) cells were cultured in DMEM (Gibco®), supplemented with 10% FBS 
(Gibco®) and penicillin-streptomycin (Gibco®) at 37°C and 5% CO2. For experiments 
conducted in 96-well plate format, the surface was coated with fetal bovine fibronectin (Thermo 
Fisher) 10 µg/ml. 
3.2.2. Protein production for the enzymatic assay 
Mettl3/Mettl14 complex was produced in HEK-293 cells, plated in 10 cm culture plates. 
Approximately 2.7 million cells were plated per culture plate and incubated until reaching 70% 
confluency. Then the cells were co-transfected with 25 µg of pcDNA3/Flag-Mettl3 (Addgene) 
and 25 µg of pcDNA3/Flag-Mettl14 (Addgene) vectors using Lipofectamine® 2000 
(Invitrogen). Cells were then incubated for 48 h. 
The Mettl3/Mettl14 complex was purified using the ANTI-FLAG® M2 Affinity Gel (Sigma-
Aldrich). The complex was eluted with 150 ng/ml 3x FLAG® peptide (Sigma-Aldrich). 
3.2.3. Mettl3/Mettl14 enzyme inhibition reaction 
All enzyme inhibition experiments were conducted in reaction buffer (20 mM Tris pH 7.5, 1 
mM DTT, 0,01% Triton™ X-100, 40 U/100 µl buffer RNaseOUT™ (Invitrogen)). The reaction 
mixture contained 200 nM unmethylated N6-adenine ss-RNA probe with a biotin tag (Integrated 
DNA Technologies), 500 nM 3H-SAM (Perkin Elmer) and 50 mM Mettl3/Mettl14 complex. 
Reaction was incubated for 20 h at 21°C on shaker. Then the reaction mixture was transferred 
to wells in streptavidin-coated 96-well plate (Perkin Elmer) and incubated 1 h at room 
temperature. After that, the plate was washed with sterile TBS 3x, and then 100 µl/well of 
scintillation fluid was added. The plate was incubated 30 min at room temperature and the 
results were obtained using 1450 MicroBeta® liquid scintillation counter (Wallack). The 
scintillation counts were proportional to amount of methylated RNA. [54] 
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3.2.4. Tetrazolium salt WST-1 assay  
 
Tetrazolium salt WST-1 (Roche®) assay was used to quantify the cell proliferation. The cells 
were cultured in 96-well plates, coated with fibronectin, with 10 000 cells seeded per well and 
incubated for overnight. Small molecules were introduced to the fresh culture media on the next 
day and incubated for 24h before the samples were collected for assays.  
The tetrazolium salt WST-1 is cleaved by mitochondrial dehydrogenases to form formazan in 
viable cells. The amount of the formazan product produced following the addition of WST-1 is 
directly related to the number of viable, metabolically active cells, enabling thus to quantify the 
cell proliferation in time.  
The WST-1 reagent was added in 1:10 dilution to the media (10 µl to 100 µl media) of cells 
treated with small molecules for 24 h. After addition of WST-1, reagent cells were placed into 
cell culture incubator at 37°C, 5% CO2 for 2 h. The spectroscopic readouts on the amount of 
formazan were taken at 1 h and 2 h time points with an ELISA reader at the wavelength 450 
nm, and with a reference at 620 nm. 
3.2.5. Imaging 
 
After cell proliferation assay, HEK-293 cells were fixed with 4% PFA for 20 min, washed with 
PBS five times and stored at 4°C in PBS. Imaging was done with AxioCam ERc5S (Zeiss) 
camera at 40x magnification. 
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4. Results and Discussion 
4.1 Molecular docking 
4.1.1. Mettl3/Mettl14 
The crystal structure of the Mettl3/Mettl14 complex with SAH (pdb:5K7W) [29] was chosen 
for the molecular modeling of potential enzyme inhibitors. The binding site of SAH was 
selected as target area for potential Mettl3/Mettl14 RNA methyltransferase complex inhibitors. 
As reported by Wang et al [29], there are several distinct regions of probable interactions 
between the ligand and enzyme. As confirmed by our molecular docking calculations, the 
amino group of the adenosyl fragment of SAH is hydrogen bonded with Asp377 of the Mettl3 
(cf. Figure 10). The binding is further supported by another bond between the adenine N1 atom 
and an adjacent peptide bond NH group. The adenine ring is sandwiched between Phe534 and 
Asn549, while many polar contacts help to hold the hydroxyl groups on the ribose as well as 
the amino and carboxyl groups of SAH [28]. The terminal amino group of SAH is acting as 
hydrogen bond donor to the Asp395 of the catalytic center of enzyme. 
 
Figure 10. The binding site of SAH. 
Based on this structure we proceeded with the search of effectively bound small molecule 
fragments. The first group of fragments consisted of various substituted purines. In variance to 
the crystal structure of SAH itself, these compounds tend to be bound to the region of the Mettl3 
protein involving Asp395, Phe534, Arg536 and Asn539 (Figure 11).  
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Figure 11. The binding site of the compound 1. 
The second group of fragments were selected based on the configuration of the protein residues, 
hydrogen bonded to the tail part of SAH. A virtual screening on ZINC [55] and DrugBank 4.0 
[56] databases was carried out using nitrogen-containing heterocycles as base structures. 
Remarkably, we found a series of fragments with piperidine and piperazine rings having 
exceptionally high docking efficiencies. The docking free energies and docking efficiencies of 
the best fragment compounds are given in Table 1. 
Table 1. The compounds with the highest docking efficiencies to Mettl3/Mettl14 complex. 
No. Compound structure G (kcal/mol) DE 
1 
 
-6.98 0.64 
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2 
 
-7.96 0.47 
3 
 
-8.67 0.62 
4 
 
-9.53 0.50 
5 
 
-5.82 0.58 
6 
 
-6.92 0.69 
7 
 
-7.41 0.67 
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4.1.2 FTO 
The crystal structure of the FTO in complex with 5-carboxy-8-hydroxyquinoline IOX1 
(pdb:4IE4) [33] was chosen for the prediction of potential efficient ligands using  molecular 
docking modeling. The ligand IOX1 was removed from the complex in order to proceed with 
the search of novel ligands. The catalytic centre of the protein involves bivalent transition metal 
ion, either Mn2+, Fe2+, Ni2+ or Zn2+. In our molecular docking simulations Zn2+ was used. The 
amino acid residues of the protein Asp233, Tyr295, Arg316 and Ser318, Arg322 were 
responsible for specific interactions between the protein and ligand (Figure 12). 
 
Figure 12. The binding site of the compound 10. 
A virtual screening on ZINC [55] database was carried out using the best known FTO inhibitors 
(I – V) as templates [57]. 
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The docking free energies and docking efficiencies of the best predicted inhibitors are given in 
Table 2. 
Table 2. The compounds with the highest docking efficiencies to FTO protein. 
No. Compound structure G (kcal/mol) DE 
8 
 
-8.78 0.49 
9 
 
-7.87 0.44 
10 
 
-7.17 0.48 
11 
 
-7.37 0.53 
12 
 
-9.45 0.47 
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It has been shown that knockout silencing of RNA demethylases FTO and AlkBH5 leads to the 
decrease of the Zika virus (ZIKV) production in cells [58]. Therefore, we suggest that apart 
from the study of inhibitory activity of the predicted compounds in FTO enzymatic and cellular 
assays, the measurements of the ZIKV inhibition could be also of significant interest.  
4.1.3 YTHDF1 
In order to develop efficient RNA m6A reader protein YTHDF1 ligands using molecular 
docking modelling, we proceeded from the crystal structure of YTHDF1 together with 
pentamer m6A RNA (pdb:4RCJ) [37]. The RNA pentamer was removed in all simulations. A 
virtual screening on ZINC [55] and DrugBank 4.0 [56] databases was carried out using N-6-
methyladenine (VI) as template.  
 
The active centre of the enzyme that embeds the methylated adenosine is located in a cavity 
surrounded by the following amino acid residues: Lys395, Ser396, Tyr397 and Asp507. The 
purine ring of potential inhibitors is sandwiched between the Tyr470 and Tyr411 residues of 
the protein (Figure 13).  
 
Figure 13. The binding site of the compound 13. 
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The best predicted RNA m6A reader YTHDF1 inhibitors (Table 3) will be experimentally 
tested in enzymatic and cellular assays. Notably, compound 15 (Cladribine) is known as an 
antiproliferative agent against hairy cell leukemia [59]. Therefore it would be highly interesting 
to establish if its mode of action is the YTHDF1 inhibition. This would enable efficient structure 
based design of novel anti-leukemia drugs. 
Table 3. The compounds with the highest docking efficiencies to the RNA m6A reader 
YTHDF1. 
No. Compound structure G (kcal/mol) DE 
13 
 
-8.01 0.57 
14 
 
-6.61 0.39 
15 
 
-6.21 0.33 
16 
 
-5.92 0.31 
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4.2 Molecular dynamics 
The molecular dynamics simulations were thereafter carried out for two compounds, 
representing the two different promising scaffolds, the compounds 2 (4-(9H-purin-6-
yloxy)aniline) and 6 (piperidine-3-carboxylate), respectively.  
In the case of compound 6 three simulations with the lengths 10 ns, 20 ns and 50 ns were carried 
out. The 50 ns simulation involved the compound in protonated form 7 that is present at 
physiological pH values. In this simulation, after 30 ns ligand an instability was observed in the 
ligand position RMSD (Figure 14a). Therefore only the first 25 ns were taken into account in 
the further trajectory and energy analysis (Figure 14b).    
 
Figure 14. The protein and ligand position root mean square deviation (RMSD) plot against 
time in the case of the Mettl3/Mettl14 complex with compound 7 for 50 ns (a) and 25 ns (b) 
runs. 
The simulation interactions diagram (Figure 15) indicates that the most important interactions 
are hydrogen bonds between the ligand and Asp395 and Lys513 residues of the Mettl3/Mettl14 
protein.  Another hydrogen bond is detected between the ligand and the carbonyl oxygen of the 
peptide bond between Leu533 and Phe534 (Figure 16). 
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Figure 15. 2D profile data for the compound 7 binding to Mettl3/Mettl14 complex: (a) 
interactions occurring more than 30 % of the simulation time; (b) timeline of interactions and 
contacts. 
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Figure 16. Interaction diagram between the compound 7 and Mettl3/Mettl14 complex. 
 
In the case of compound 2 the simulation with the length 50 ns was carried out. The rather 
constant plot of position RMSD for both the protein and ligand after 10 ns indicates that the 
system has achieved steady state. 
 
Figure 17. The protein and ligand position root mean square deviation (RMSD) plot against 
time in the case of the Mettl3/Mettl14 complex with compound 2 for 50 ns. 
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The protein-ligand interaction profile for the compound 2 (Figure 18) indicates that the main 
interactions with Mettl3/Mettl14 involve the Arg379, Glu413 and Asn549 residues of the 
protein. Interestingly, the interaction of Arg379 with ligand involves the contributions from the 
hydrogen bonding as well as from the ionic and hydrophobic interactions. The Glu413 and 
Asn549 residues are involved in hydrogen bonding as acceptors.   
 
Figure 18. 2D profile data for the compound 2 binding to Mettl3/Mettl14 complex. 
Interactions occurring more than 30 % of the simulation time (a). Timeline of interactions and 
contacts (b). 
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These observations are depicted in the interaction diagram given in Figure 19. 
 
Figure 19. Interaction diagram between the compound 2 and Mettl3/Mettl14 complex. 
 
In order to further specify the nature of the ligand-protein interactions, the Molecular 
Mechanics/Poisson–Boltzmann Surface Area (MMPBSA) [60] binding energy calculations 
were carried out using data from molecular dynamics simulations. In MM/PBSA, the free 
energy of a state (ligand or enzyme) is estimated from the following sum  
𝐺 = 𝐸𝑏𝑛𝑑 +  𝐸𝑒𝑙 + 𝐸𝑣𝑑𝑊 + 𝐺𝑝𝑜𝑙 + 𝐺𝑛𝑝 − 𝑇𝑆             (3) 
where the first three terms are standard molecular mechanics energy terms from bonded (bond, 
angle and dihedral), electrostatic and van der Waals interactions. Gpol and Gnp are the polar and 
non-polar contributions to the solvation free energies. Gpol is typically obtained by solving the 
Poisson-Bolzmann equation or by using the generalized Born (GB) model (giving the 
MM/GBSA approach), whereas the non-polar term is estimated from a linear relation to the 
solvent accessible surface area. The last term in above equation is the absolute temperature, T, 
multiplied by the entropy, S, estimated by a normal-mode analysis of the vibrational 
frequencies. The results for the lowest binding energy states are given in Table 4.  
 
 
 
33 
 
Table 4. The MMPBSA energies for the Mettl3 complexes with the compounds 2 and 7 
(kcal/mol). 
Energy term 2 7 
Δ𝐸𝑣𝑑𝑊 -23.72 -8.48 
Δ𝐸𝑒𝑙 -16.74 -25.26 
Δ𝐸𝑝𝑜𝑙 22.53 25.56 
Δ𝐸𝑛𝑝 -8.36 -7.37 
Δ𝐺𝑏𝑖𝑛𝑑 -27.95 -15.51 
 
The total binding energies are large for both compounds and predict significant biological 
effects. However, it is interesting to compare the contributions arising from different physical 
interactions to the binding energies. For the compound 7, the electrostatic interaction energy 
between the ligand and enzyme and the polar (de)solvation energy almost exactly cancel each 
other. The binding energy is thus primarily determined by large van der Waals and nonpolar 
solvation terms. Thus, this relatively small compound is strongly bound to the enzyme due to 
specifically oriented van der Waals and nonpolar solvation (lipophilic) interactions.   
In the case of the compound 2, the main contributions to the binding free energy with protein 
are the electrostatic energy and the van der Waals interaction energy (Table 4). The latter is 
considerably higher than in the case of smaller ligand 7. Notably, the polar (de)solvation energy 
and the nonpolar solvation energies are similar for both compounds studied. 
 
4.3. Mettl3/Mettl14 complex inhibition assay results 
4.3.1 Enzymatic assay results  
The enzymatic assay studies on Mettl3/Mettl14 complex were carried out using the tritiated 3H-
SAM (Perkin Elmer) reaction with the unmethylated RNA. The preliminary results were 
obtained for the studied inhibitory compounds at 10nM and 10M concentrations. The 
estimated IC50 values are given in Table 5. 
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Table 5. The inhibition of Mettl3/Mettl14 complex in enzymatic assay. 
Compound %inh (10nM) IC50 (nM) 
1 16.7 30 
2 24.0 21 
3 N/Aa N/A 
4 4.1 122 
5 15.5 32 
a Toxic compound 
These results reveal the inhibitory activity of compounds 1, 2 and 5 at nanomolar level and 
make them prospective leads for the further structural optimization of the RNA 
methyltransferase Mettl3/Mettl14 inhibitors. 
4.3.2 Cellular assay results  
Within this work, the activity of the designed Mettl3/Mettl14 inhibitors on the cell proliferation 
was studied using WST-1 assay. It has been shown that the genetic inactivation or depletion of 
mouse and human Mettl3 enzyme promotes self-renewal and hinders differentiation of the 
embryonic stem cells [61]. Therefore, it is expected that the inhibition of the Mettl3 in somatic 
cells would lead to the increase of the proliferation. In Figure 20, the concentration dependence 
of the HEK-293 cell proliferation extent is given for the compounds 1-5 as measured by the 
absorbance in the WST-1 assay.  
The compound 1 (methyl 6-methylpiperidine-3-carboxylate) has caused significant increase of 
the proliferation of cells at all measured concentration (100 nM, 1 nM and 1 pM) as compared 
to non-treated control (Figure 20). The amount of the proliferated cells increases in time but 
remains nearly constant after two hours. A notable increase of the cell proliferation at just 1 pM 
inhibitor concentration reflects very high efficiency of this compound and can be taken as the 
lead compound for the further structure optimization.  
A similar behavior was observed in the case of compound 2 (Figure 21). As this compound 
belongs to the different scaffold, it can be also used as a lead compound for the further 
optimization of the Mettl3/Mettl14 complex inhibitors.  
The compound 3 (tert-butyl 6-methylpiperidine-3-carboxylate) has unusual concentration 
dependence of the WST-1 assay readout, having a maximum at the 1 nM concentration (Figure 
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22). Whereas this compound is also an efficient proliferation enhancer, it is obviously toxic at 
higher concentrations. The compounds 4 (3-Amino-4-chloro-N-(m-tolyl)benzenesulfonamide) 
and 5 (methyl piperazine-2-carboxylate) have little effect on the HEK-293 cell proliferation at 
all concentrations studied (Figure 23 and Figure 24). 
 
Figure 20. The proliferation efficiency of methyl 6-methylpiperidine-3-carboxylate 1 on 
HEK-293 cells. 
 
Figure 21. The proliferation efficiency of 4-(9H-purin-6-yloxy)aniline) 2 on HEK-293 cells.  
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Figure 22. The proliferation efficiency of tert-butyl 6-methylpiperidine-3-carboxylate 3 on 
HEK-293 cells.  
 
Figure 23. The proliferation efficiency of 3-Amino-4-chloro-N-(m-tolyl)benzenesulfonamide 
4 on HEK-293 cells.  
0
0.5
1
1.5
2
2.5
1 2
A
b
so
rb
a
n
ce
Time (h)
Non-treated control
1µM
1nM
1pM
0
0.2
0.4
0.6
0.8
1
1.2
1 2
A
b
so
rb
a
n
ce
Time (h)
Non-treated control
1µM
 1nM
1pM
 
37 
 
 
Figure 24. The proliferation efficiency of methyl piperazine-2-carboxylate 5 on HEK-293 
cells.  
The effect of studied compounds on the cell proliferation can be clearly seen also by examining 
the images of the cell cultures. As compared to the negative control, i.e. no inhibitor added 
(Figure 25, a) to the HEK-293 cell culture, the cell cultures with 1 M (Figure 25,b) and 0.75 
nM (Figure 25,c) added have after 24 hours substantial increase in the number of cells as well 
as higher regularity. 
 
Figure 25. Images of the HEK-293 cell cultures at 24 hours after addition of compound 1 (in 
0.05% DMSO): no compound added (a); 1 M compound added (b); 0.75 nM compound 
added (c). 
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These results demonstrate that compounds 1 (methyl piperidine-3-carboxylate) and 2 (4-(9H-
purin-6-yloxy)aniline) have significant effects on cell proliferation at low nanomolar 
concentrations and may thus have valuable medical applicability as supporters of the tissue 
regeneration. 
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5. Summary 
 
Recent studies have shown that RNA m6A methylation plays significant and broad role in 
various physiological processes, such as development, fertility, carcinogenesis, stemness, early 
mortality, meiosis and circadian cycle, and links to obesity, cancer, and other human diseases 
[20]. The detailed investigation and development of chemical agents regulating this process is 
therefore of large biological and medical importance. Thus the goal of the present work was to 
design the inhibitory ligands for the enzymes regulating the RNA adenosine N6-methylation 
using methods of computational chemistry. The molecular docking using AutoDock 4.2 
software was used to locate the potential ligand binding sites of the RNA methyltransferase 
complex Mettl3/Mettl14, RNA demethylase FTO and RNA “reader” protein YTHDF1. A 
virtual screening on the large compound databases ZINC, MolPort and DrugBank 4.0 was 
carried out to identify compounds structurally fitting to predicted binding sites. The best 
docking efficiencies were found for a series of piperidine and piperazine derivatives binding to 
the methyltransferase Mettl3/Mettl14 complex. Because of large potential biomedical 
importance of the RNA methylation inhibitors, the study was then concentrated on these 
compounds. The molecular dynamics simulations using the Desmond 4.2 code within 
Schrödinger LLC Maestro program was carried out for two compounds representing the most 
promising scaffolds. The results of the simulations enabled to detail the specific ligand-protein 
interactions for the further structure optimization of inhibitors. The biological activity for five 
predicted potential inhibitors of the Mettl3/Mettl14 complex was investigated using the 
tetrazolium salt WST-1 (Roche®) assay that quantifies the cell proliferation. Two compounds 
(methyl piperidine-3-carboxylate and 4-(9H-purin-6-yloxy)aniline) exhibited high proliferation 
enhancing activity on human embryonic kidney HEK-293 cells, even at nanomolar 
concentration level. The promotion of the cell proliferation by Mettl3/Mettl14 complex 
inhibitors was also demonstrated using morphological cell culture imaging studies. The best 
designed compounds are the first known RNA methyltransferase complex Mettl3/Mettl14 
inhibitors and therefore of high interest for further biochemical, cellular and in vivo studies.  
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6. Kokkuvõte 
 
Hiljutised uuringud on näidanud, et RNA adenosiini N6-metüleerimine omab olulist rolli 
paljudes füsioloogilistes protsessides nagu näiteks meioos, organismi areng, viljakus, 
kartsinogenees, tüvirakulisus, varajane suremus ja ööpäevased tsüklid ning seondub 
ülekaalulisuse, vähihaiguse ja paljude teiste haigustega. Seetõttu on RNA metüleerimist 
reguleerivate keemiliste agentide uurimine ja väljaarendamine suure bioloogilise ja praktilise 
meditsiinilise tähtsusega. Käesoleva töö eesmärgiks oli seega leida inhibeerivaid 
madalmolekulaarseid ligande RNA adenosiini N6-metüleerimist reguleerivatele ensüümidele, 
kasutades selleks arvutikeemia meetodeid. Molekulaarsildamise programmi AutoDock 4.2 abil 
selgitati välja potentsiaalsed ligandide sidumiskohad RNA metüültransferaasi kompleksile 
Mettl3/Mettl14, RNA demetülaasile FTO ning RNA „lugeja“ valgule YTHDF1. Keemiliste 
ühendite suurtest andmebaasidest ZINC, MolPort ja DrugBank 4.0 leiti virtuaalse sõelumise 
teel ennustatud sidumiskohtadesse sobivad ligandid. Parimate sildamise efektiivsustega (DE > 
0.5) olid mitmed Mettl3/Mettl14 kompleksile seonduvad piperidiini ja piperasiini derivaadid. 
RNA metüleerimise inhibiitorite suure biomeditsiinilise tähtsuse tõttu keskenduti edasises 
uuringus just neile ühenditele. Kahe parema erineva põhistruktuuriga ühendi jaoks viidi läbi 
molekulaardünaamika arvutused Schrödinger LLC Maestro tarkvaras oleva Desmondi 
programmi abil. Arvutuste tulemused võimaldasid täpsustada spetsiifilisi ligand-valk 
interaktsioone, mis on olulised inhibeerivate ligandide struktuuri edasiseks optimeerimiseks. 
Viie ennustatud Mettl3/Mettl14 kompleksi inhibiitori bioloogilist aktiivsust uuriti, kasutades 
tetrasooliumi soola WST-1 (Roche®) testi, mis võimaldab määrata rakkude proliferatsiooni 
taset. Kaks ühendit (metüül-piperidiin-3-karboksülaat ja 4-(9H-puriin-6-üüloksü)aniliin) 
omasid suurt proliferatsiooni taset tõstvat võimet inimese embrüonaalsetele neerurakkudele 
HEK-293, isegi nanomolaarse kontsentratsiooni tasemel. Rakkude proliferatsiooni kasv 
Mettl3/Mettl14 kompleksi inhibiitorite toimel oli selgelt detekteeritav ka rakukultuuride 
morfoloogilistes uuringutes. Parimad leitud ühendid on esimesed teadaolevad RNA 
metüültransferaasi Mettl3/Mettl14 kompleksi inhibiitorid ning pakuvad seega suurt huvi 
edasisteks biokeemilisteks, raku- ja loomkatseteks. 
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